Mitsubishi Tanabe Pharma
(MTPC) will use Affectis
Pharmaceuticals’ behavioral pharmacology expertise and technology in its drug discovery efforts. Affectis will receive research fees and is eligible to developmental milestones.
MTPC’s ongoing drug discovery program is reportedly based on a novel depression
target that Affectis helped validate in a previous collaboration. The deal, which was inked in February 2005, covered the use of Affectis’ Behavioural Interference™ platform.
Under the new agreement, MTPC will continue to utilize this technology and Affectis’ expertise. Affectis has two antidepressant discovery programs and one Phase II candidate for depression.